Fundraising Fox
/Companies
Sign in

Talus Bio

YC S21

Seattle, US · Founded 2020 · Delaware corporation · 16 employees · 19 known investors

Find your way into Talus Bio

Sign up to see every warm intro you have to Talus Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Talus Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

Also known as Talus Bioscience, Inc.

AI & Machine LearningBiotechDeep TechHealthtechGenomicsDrug discoveryUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (S21)

Talus Bio was founded in 2020 by Alex Federation, Lindsay Pino, Alex Federation, Ph.D., and Lindsay Pino, Ph.D..

AFAlex Federation
Alex FederationFounderHe trained in medicinal chemistry, drug screening, and drug development under Jay Bradner at Harvard, and subsequently studied epigenomics and proteomics in Seattle before developing the company's gene regulator platform.
LPLindsay Pino
Lindsay PinoFounderLindsay Pino is Chief Technology Officer at Talus Bio, focusing on quantitative proteomics and scaling experimental approaches. He trained at the Broad Institute, University of Washington, and University of Pennsylvania.
AF
Alex Federation, Ph.D.Chief Executive Officer & Co-Founder
LP
Lindsay Pino, Ph.D.Chief Technology Officer & Co-Founder
CJChristopher Joyce
Christopher JoyceFounder
MBMichelle Briscoe
Michelle BriscoeFounder
WFWill Fondrie
Will FondrieFounder

Board

OAOmri Amirav-Drory
Omri Amirav-DroryBoard directorGeneral Partner at NFX
JSJ. Seth Strattan
J. Seth StrattanBoard directorGeneral Partner at Two Bear Capital

Investors · 19

Fifty Yearslisted by Fifty YearsSan Francisco · $250K – $2M

How we know: Fifty Years's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

FundersClublisted by FundersClubSan Francisco · $290K

How we know: FundersClub's portfolio page · Y Combinator's founder network · Not right? Tell us

Gaingelslisted by GaingelsNew York · $200K – $500K

How we know: gaingels.com · Not right? Tell us

Jude Gomilalisted by Jude GomilaLynnwood

How we know: Jude Gomila's portfolio page · Not right? Tell us

NFXlisted by NFXSan Francisco · $250K – $5Mvia Omri Drory · board

How we know: board seat on SEC Form D · funding news · Y Combinator's founder network · Not right? Tell us

Pioneerlisted by PioneerToronto, Ontario

How we know: Y Combinator's founder network · pioneerfund.vc · open dataset · 5k.vc investor directory · Not right? Tell us

Planet 9 Capitallisted by Planet 9 CapitalBergen

How we know: Planet 9 Capital's portfolio page · Y Combinator's founder network · Not right? Tell us

Two Bear Capitallisted by Two Bear CapitalWhitefish · $3M – $10M

How we know: Two Bear Capital's portfolio page · funding news · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Axial VCreportedSan Francisco · $100K – $5M

How we know: Y Combinator's founder network · Not right? Tell us

Boom Capitalreported

How we know: Y Combinator's founder network · Not right? Tell us

BoxOne VenturesreportedMontréal · $500K

How we know: the VCSheet dataset · Not right? Tell us

FAST — by GETTYLABreportedSan Francisco · $100K

How we know: Y Combinator's founder network · Not right? Tell us

Harvard Management CompanyreportedAllston

How we know: Y Combinator's founder network · Not right? Tell us

Lightspeed Venture PartnersreportedMenlo Park · $1M – $5M

How we know: Y Combinator's founder network · Not right? Tell us

North South VenturesreportedToronto

How we know: Y Combinator's founder network · Not right? Tell us

Pack VenturesreportedSeattle

How we know: Y Combinator's founder network · Not right? Tell us

WRF CapitalreportedSeattle · $100K – $2M

How we know: Y Combinator's founder network · Not right? Tell us

Funding

SEC filings, press & company announcements

$9.4M disclosed across 1 of 2 rounds · 2022–2024

▶$9.4MraisedAug 2024 · 11 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lindsay PinoExecutive Officer, Director
  • Michelle BriscoeExecutive Officer
  • Alex FederationExecutive Officer, Director, Promoter
  • Omri Amirav-DroryDirector
  • J. Seth StrattanDirector
Offering amount
$11.3M
Amount sold
$9.4M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Talus Bio went on to found or lead other companies.

Omri DroryDirectorFounded Renewal BioMilad AlucozaiBoard MemberFounded Revalia Bio, Inc.

Related companies · 7

Anto BiosciencesAnto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.
Arpeggio BioArpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
Sequence BioSequence Bio discovers genetic causes of disease within Newfoundland and Labrador's founder population to develop breakthrough treatments, diagnostics, and preventions. The company focuses on translational biology and genetics research for patients globally.
Ochre BioOchre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models. The company aims to address the global shortage of liver transplants by developing new treatment options for liver fibrosis and cirrhosis.
LatusLatus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise. The company operates from Philadelphia and Boston, serving the biotechnology and therapeutics industry.
CircumventCircumvent develops precision medicines for neurodegenerative diseases, with current focus on Batten Disease and other rare neurological disorders. The company's research targets synaptic dysfunction and lysosomal pathways through investigation of the palmitoylome.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Talus Bio.

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$398.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$307.5K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2022$455K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$333.9K
National Science FoundationPhase I2021$255.8K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure
Talus Bioscience, Inc.

In the news

Talus Bioscience lands $4.3M in grant funding for drug discovery platform – GeekWiregeekwire.com · Aug 2023Talus Announces Close of Seed Funding Round and Hires New COO | Talus Bio - Biotechnology & Drug Discoverytalus.bio · Jun 2022Inspired by scientist CEOs, Seattle startup lands $9.75M to build up drug discovery platform – GeekWiregeekwire.com · Jun 2022

Frequently asked questions

What does Talus Bio do?
Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Who founded Talus Bio?
Talus Bio was founded by Alex Federation, Lindsay Pino, Alex Federation, Ph.D., Lindsay Pino, Ph.D. in 2020.
Who are Talus Bio's investors?
Talus Bio's investors include Farvatn Venture, Fifty Years, FundersClub, Gaingels, Jude Gomila, NFX, Pioneer, Planet 9 Capital and 11 more.
How much funding has Talus Bio raised?
Talus Bio has disclosed $9.4M raised across 1 of its 2 known rounds.
Where is Talus Bio headquartered?
Talus Bio is headquartered in Seattle, US.